Clinical trials: Androgen Deficiency
Known Androgen Deficiency
Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men
Low testosterone is a common male problem. The diagnosis of low testosterone often requires blood sampling and expensive testing. We want to know if measuring saliva testosterone can be used in place of blood sampling.
- Trial name
- NCT01909505
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Saliva Biomarkers, Inc.
Healthy Subjects, Androgen Deficiency
Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males
This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses
- Trial name
- NCT00540553
- Testing
- GSK971086
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypogonadism, Androgens
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)
In this study we have evaluated the effects of three different doses of oral testosterone undecanoate in aging men presenting with a combination of symptoms suggestive of hypogonadism and low blood levels of the male hormone…
- Trial name
- NCT00434824
- Testing
- Oral testosterone undecanoate (Andriol)
- Volunteers
- 322 people
- Sponsor
- Merck Sharp & Dohme LLC
Hormone-Sensitive Prostate Cancer
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in…
- Trial name
- CAPItello-281 (NCT04493853)
- Testing
- Capivasertib, Abiraterone Acetate
- Where
- 323 sites in United States, Argentina and 30 more
- Volunteers
- 1,012 people
- Sponsor
- AstraZeneca
Hypogonadism, Hypogonadism, Male
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone administered with and without dutasteride
- Trial name
- NCT00400335
- Testing
- Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypogonadism, Hypogonadism, Male
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the effect of 28-day repeat dosing of this combination with varying BID doses of testosterone (T), in combination…
- Trial name
- NCT00398580
- Testing
- Nanomilled testosterone, Nanomilled dutasteride, commercially available dutasteride
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- GlaxoSmithKline
Androgens (Deficiency), Male
Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)
The purpose of this study is to investigate the effect of a testosterone replacement therapy called Testogel in men with PADAM. The effects on body composition (lean, fat and bone) and other symptoms of PADAM and safety will be…
- Trial name
- NCT00185198
- Testing
- Testogel (Testosterone, BAYV001915)
- Where
- 30 sites in Austria, Finland and 6 more
- Volunteers
- 363 people
- Sponsor
- Bayer
Male Hypogonadism
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism
DITEST is an oral formulation of native testosterone for the treatment of androgen deficiency in men. The study was a Phase 1 clinical study in hypogonadal men, defined according to FDA and Endocrine Society Guidelines, designed…
- Trial name
- NCT02966652
- Testing
- DITEST, Testosterone undecanoate
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Neurocrine UK Limited
Pharmacokinetics, Hormone Deficiency
Pharmacokinetics of a Novel Vaginal Delivery System for Testosterone and Dehydroepiandrosterone (DHEA)
This study was performed to determine the pharmacokinetic parameters of vaginal rings that contain DHEA, testosterone, or combinations of both androgens, in comparison to the oral administration of DHEA and the transdermal…
- Trial name
- NCT03967964
- Testing
- Dehydroepiandrosterone 2.2 g, Dehydroepiandrosterone 1.5 g/Testosterone 25 mg, Testosterone
- Where
- Chile
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Laboratorios Andromaco S.A.
SARS-CoV 2, COVID
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS).
- Conditions
- SARS-CoV 2, COVID, COVID-19, Androgenetic Alopecia
- Trial name
- NCT04368897
- Testing
- CAG length <22, CAG length >=22
- Where
- Spain
- Sponsor
- Applied Biology, Inc.